The high H-score for IL13Rα2 in GBM, especially in conjunction with the poor prognostic markers of WT IDH-1 WT and unmethylated MGMT, encourage us to move forward in planning a clinical trial for recurrent MG. Here, IL13RA2 is linked to myasthenia gravis.